

Product Data Sheet

Product Name: AM 281
Cat. No.: GC16480

Chemical Properties

Cas. No. 202463-68-1

Chemical Name 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-morpholino-1H-pyrazole-3-carboxamide

SMILES IC1=CC=C(C=C1)C2=C(C)C(C(NN3CCOCC3)=O)=NN2C(C(Cl)=C4)=CC=C4Cl


Formula $C_{21}H_{19}Cl_2IN_4O_2$ M.Wt 557.22

Solubility $\geq 1.86\text{mg/mL}$ in DMSO with ultrasonic and warming Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Protocol

Cell experiment [1]:

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Cell lines	Rat embryonic ventricular myocardial H9c2 cells
Preparation Method	AM 281 (1, 2, 4 $\mu\text{mol/L}$) pre-treats rat embryonic ventricular myogenic H9c2 cells for 2h, followed by co-incubation with doxorubicin (DOX, 1 or 5 μM) for 18h.
Reaction Conditions	0, 1, 2, and 4 $\mu\text{mol/L}$; 20h
Applications	AM 281 significantly prevented cell death and apoptosis induced by doxorubicin (DOX) in H9c2 cells.

Animal experiment [2]:

Animal models	C57BL/6J mice and inducible nitric oxide synthase (iNOS) knockout (KO) mice
Preparation Method	Male C57BL/6J and iNOS KO mice (8–12 weeks old) were used. For the fear conditioning experiment, mice were subjected to contextual fear conditioning (CFC) by exposing them to three inescapable electrical footshocks (0.75mA, 2 seconds each) in a conditioning chamber. Freezing behavior was evaluated 24, 48, 72, and 96 hours after conditioning. For drug treatment, AM 281 (1, 2, and 4mg/kg) was administered intraperitoneally (i.p.) 30 minutes before the first reexposure to the context chamber.
Dosage form	1, 2, and 4mg/kg; i.p

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Applications AM 281 (1mg/kg) significantly increased freezing behavior in wild-type (WT) mice during contextual fear conditioning, indicating enhanced fear expression. However, in iNOS KO mice, AM 281 did not alter baseline freezing behavior but facilitated fear extinction when administered before reexposure to the context chamber.

References:

- [1] Mukhopadhyay P, Bátkai S, Rajesh M, et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol. 2007 Aug 7;50(6):528-36.
- [2] Lisboa SF, Gomes FV, Silva AL, et al. Increased Contextual Fear Conditioning in iNOS Knockout Mice: Additional Evidence for the Involvement of Nitric Oxide in Stress-Related Disorders and Contribution of the Endocannabinoid System. Int J Neuropsychopharmacol. 2015 Jan 24;18(8):pyv005.

Background

AM 281 is a high-affinity and selective CB2 receptor antagonist with an IC_{50} of $13\mu M$ ^[1]. AM 281 is used to study the role of the endocannabinoid system in various physiological and pathological processes and has potential applications in the research of inflammation, pain, and neurodegenerative diseases^[2]. AM 281 selectively activates the CB2 receptor, which is mainly expressed in immune cells and peripheral tissues, while having minimal activation of the CB1 receptor expressed in the central nervous system^[3]. AM 281 has been shown to modulate immune responses and has potential therapeutic applications in diseases related to the endocannabinoid system^[4].

In vitro, AM 281 ($2\mu M$) was used to pre-treat myocardial HL-1 cells for 30 minutes, followed by co-incubation with quetiapine (Que, $2\mu M$) for 24 hours. AM 281 significantly reduced quetiapine-induced myocardial cell damage. AM 281 inhibited the activation of necroptosis by reducing the protein levels of RIP3 and MLKL and inhibiting the phosphorylation of MLKL in myocardial cells. Additionally, AM 281 significantly decreased inflammation and fibrosis in myocardial cells, improving their pathological

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

state^[5]. AM 281 (1, 2, and 4 μ mol/L) was used to pre-treat rat embryonic ventricular myocardial-derived H9c2 cells for 2 hours, followed by co-incubation with doxorubicin (DOX, 1 or 5 μ M) for 18 hours. AM 281 significantly increased cell viability and inhibited DOX-induced DNA damage and apoptosis^[6].

In vivo, AM 281 (0.62, 1.25, and 2.5mg/kg) was administered via intraperitoneal injection to mice that had been treated with morphine (30-90mg/kg) for 3 consecutive days. AM 281 (2.5mg/kg) significantly improved the recognition index (RI) and alleviated memory deficits in mice undergoing spontaneous morphine withdrawal by inhibiting the activation of CB1 receptors^[7]. AM 281 (1, 2, and 4mg/kg) was administered via intraperitoneal injection 30 minutes before the first re-exposure to the aversive context in mice. The results showed that AM 281 at a dose of 1mg/kg significantly increased freezing behavior (fear response) in mice^[8].

References:

- [1] Kadoi Y, Hinohara H, Kunimoto F, et al. Cannabinoid antagonist AM 281 reduces mortality rate and neurologic dysfunction after cecal ligation and puncture in rats. Crit Care Med. 2005 Nov;33(11):2629-36.
- [2] Droste SM, Saland SK, Schlitter EK, et al. AM 251 differentially effects food-maintained responding depending on food palatability. Pharmacol Biochem Behav. 2010 Jun;95(4):443-8.
- [3] Rutkowska M, Jamontt J, Gliniak H. Effects of cannabinoids on the anxiety-like response in mice. Pharmacol Rep. 2006 Mar-Apr;58(2):200-6.
- [4] Gifford AN, Bruneus M, Gatley SJ, et al. Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther. 1999 Feb;288(2):478-83.
- [5] Li X, Peng Z, Zhou Y, Wang J, et al. Quetiapine induces myocardial necroptotic cell death through bidirectional regulation of cannabinoid receptors. Toxicol Lett. 2019 Oct 1;313:77-90.
- [6] Mukhopadhyay P, B tkai S, Rajesh M, et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol. 2007 Aug 7;50(6):528-36.
- [7] Vaseghi G, Rabbani M, Hajhashemi V. The effect of AM281, a cannabinoid antagonist, on memory performance during spontaneous morphine withdrawal in mice. Res Pharm Sci. 2013 Jan;8(1):59-64.
- [8] Lisboa SF, Gomes FV, Silva AL, et al. Increased Contextual Fear Conditioning in iNOS Knockout Mice: Additional Evidence for the Involvement of Nitric Oxide in Stress-Related Disorders and Contribution of the Endocannabinoid System. Int J Neuropsychopharmacol. 2015 Jan

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

24;18(8):pyv005.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA